The Patent Finder

FCB Pharmicell Co., Ltd.

Also on record
Records under this name other than patents FCB Pharmicell Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 4 of 4 · Back to FCB Pharmicell Co., Ltd.

PatentTitleStatus Expires Confidence
US 7,229,827Method for differentiating mesenchymal stem cells into neural cells
Formerly held
Term ended
Term ended Jan 16, 2024 · From the USPTO record
Term endedTerm ended Jan 16, 2024From the USPTO record
US 7,390,658CD8α+lymphoid dendritic cell differentiated from human hematopoietic stem cell and a method for differentiation
Formerly held
Term ended
Term ended Jul 26, 2022 · From the USPTO record
Term endedTerm ended Jul 26, 2022From the USPTO record
US 7,635,591Method for differentiating mesenchymal stem cell into neural cell and pharmaceutical composition containing the neural cell for neurodegenerative disease
Formerly held
Lapsed on the fee record
Ended Dec 22, 2017 · From the USPTO record
Lapsed on the fee recordEnded Dec 22, 2017From the USPTO record
US 7,390,800Adenosine deaminase inhibitor and novel Bacillus sp. Iada-7 strain which produces it
Formerly held
Lapsed on the fee record
Ended Jun 24, 2016 · From the USPTO record
Lapsed on the fee recordEnded Jun 24, 2016From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited